# DIalysis Symptom COntrol-Restless Legs Syndrome Trial

> **NCT03806530** · PHASE3 · COMPLETED · sponsor: **Population Health Research Institute** · enrollment: 52 (actual)

## Conditions studied

- End Stage Renal Disease
- Restless Legs Syndrome

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Ropinirole
- **DRUG:** Placebo Gabapentin
- **DRUG:** Placebo Ropinirole

## Key facts

- **NCT ID:** NCT03806530
- **Lead sponsor:** Population Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2021-12-14
- **Final completion:** 2022-07-19
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03806530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03806530, "DIalysis Symptom COntrol-Restless Legs Syndrome Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03806530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*